Omeros Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMER research report →
About the company
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates.
- CEO
- Gregory A. Demopulos
- IPO
- 2009
- Employees
- 202
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $671.64M
- P/E
- 7.14
- P/S
- 67.89
- P/B
- -10.54
- EV/EBITDA
- 10.55
- Div Yield
- 0.00%
- Gross Margin
- -12.39%
- Op Margin
- -1063.86%
- Net Margin
- 871.02%
- ROE
- -54.39%
- ROIC
- -40.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-3,350,000 · 97.86%
- EPS
- $-0.05 · 98.05%
- Op Income
- $-122,796,000
- FCF YoY
- 22.02%
- 52W High
- $17.65
- 52W Low
- $3.00
- 50D MA
- $11.77
- 200D MA
- $10.36
- Beta
- 2.55
- Avg Volume
- 1.75M
Get TickerSpark's AI analysis on OMER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Shah Rajiv | other | 15,000 |
| Jun 18, 26 | Perkinson Diana T. | other | 15,000 |
| Jun 18, 26 | Hood Leroy E. MD PhD | other | 15,000 |
| Jun 18, 26 | HANISH ARNOLD C | other | 15,000 |
| Jun 18, 26 | Demopulos Peter A MD | other | 15,000 |
| Jun 18, 26 | Cable Thomas J. | other | 15,000 |
| Jun 18, 26 | Bumol Thomas F. | other | 15,000 |
| May 22, 26 | Cable Thomas J. | other | 7,500 |
| May 22, 26 | Cable Thomas J. | sell | 7,500 |
| May 22, 26 | Cable Thomas J. | other | 7,500 |
Our OMER coverage
Recent articles, reports, and earnings notes.
No research on OMER yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OMER report →Similar companies
Peers in the same neighborhood.